Democratic Republic of the Congo

Population 2018  84 million

<table>
<thead>
<tr>
<th>Estimates of TB burden*, 2018</th>
<th>Number (thousands)</th>
<th>Rate (per 100 000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total TB incidence</td>
<td>270 (175–385)</td>
<td>321 (208–458)</td>
</tr>
<tr>
<td>HIV-positive TB incidence</td>
<td>31 (9.4–65)</td>
<td>37 (11–77)</td>
</tr>
<tr>
<td>MDR/RR-TB incidence**</td>
<td>6 (3–10)</td>
<td>7.2 (3.6–12)</td>
</tr>
<tr>
<td>HIV-negative TB mortality</td>
<td>43 (25–65)</td>
<td>51 (30–77)</td>
</tr>
<tr>
<td>HIV-positive TB mortality</td>
<td>10 (3.2–22)</td>
<td>12 (3.8–26)</td>
</tr>
</tbody>
</table>

Estimated proportion of TB cases with MDR/RR-TB, 2018

<table>
<thead>
<tr>
<th>New cases</th>
<th>1.7% (1.1–2.6)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Previously treated cases</td>
<td>9.5% (8.8–10)</td>
</tr>
</tbody>
</table>

TB case notifications, 2018

Total new and relapse  169 748
- % tested with rapid diagnostics at time of diagnosis  7%
- % with known HIV status  60%
- % pulmonary  83%
- % bacteriologically confirmed***  77%
- % children aged 0-14 years  11%
- % women  39%
- % men  50%

Universal health coverage and social protection

TB treatment coverage (notified/estimated incidence), 2018  63% (44–97)

TB patients facing catastrophic total costs

TB case fatality ratio (estimated mortality/estimated incidence), 2018  20% (10–33)

TB/HIV care in new and relapse TB patients, 2018

Patients with known HIV status who are HIV-positive  9 758  9%
- on antiretroviral therapy  8 481  87%

Drug-resistant TB care, 2018

% of bacteriologically confirmed TB cases tested for rifampicin resistance ***
- New cases  2%
- Previously treated cases  66%

Laboratory-confirmed cases*  MDR/RR-TB: 765, XDR-TB: 22

Patients started on treatment**  MDR/RR-TB: 690, XDR-TB: 15

MDR/RR-TB cases tested for resistance to second-line drugs  328

Treatment success rate and cohort size

New and relapse cases registered in 2017  90%  149 657
Previously treated cases, excluding relapse, registered in 2017  70%  1 593
HIV-positive TB cases registered in 2017  78%  9 688
MDR/RR-TB cases started on second-line treatment in 2016  86%  634
XDR-TB cases started on second-line treatment in 2016  39%  18

TB preventive treatment, 2018

% of HIV-positive people (newly enrolled in care) on preventive treatment  39%
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment  24% (22–26)

TB financing, 2019

National TB budget (US$ millions)  44
Funding source: 4% domestic, 55% international, 41% unfunded

* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Calculated for pulmonary cases only
* Includes cases with unknown previous TB treatment history
** Includes patients diagnosed before 2018 and patients who were not laboratory-confirmed

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
Generated: 2020-02-24
Data: www.who.int/tb/data